Hello, everyone, and nice to see you again after what was an extended holiday break for some of us on this side of the pond. We hope those of you who were able to indulge enjoyed a refreshing respite, because a serious game of catch-up is now underway. This calls, of course, for a cup or three of stimulation. Our chosen flavor this morning is apple cider donut, for those keeping track. Meanwhile, here are some tidbits to get you started. Have a smashing day and do stay in touch …

Pfizer (PFE) may sell its consumer health care business. The drug maker says it is reviewing “strategic alternatives” that may include a full or partial separation through a spinoff, sale, or some other transaction. Of course, Pfizer may decide to keep the business, which generated $3.4 billion in sales last year, or about 6 percent of total revenue. The unit sells such well-known brands as Advil, Nexium, Robitussin, and Chapstick.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Since the chain pharmacies are losing market share of OTC drugs to online sales, and since Amazon plans to get into selling Rx drugs, the purchase of Pfizer’s consumer products by Amazon would be a good 1-2 punch for their business.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy